Glenmark Pharmaceuticals subsidiary Glenmark Specialty has entered an exclusive agreement to market and distribute two Beigene oncology medicines in India.

Tislelizumab and Zanubrutinib will be commercialised by Glenmark in the country.

The strategic collaboration will see Glenmark taking charge of the development, registration and distribution processes to bring these cancer treatments to Indian patients.

Glenmark Pharmaceuticals India formulations president and business head Alok Malik stated: “We are excited about our partnership with BeiGene, signifying our commitment to advancing healthcare in India.

“The addition of Tislelizumab and Zanubrutinib to our oncology portfolio underscores our dedication to the cancer patients’ community and our commitment to provide access to novel therapies across India.”

Tislelizumab is a humanised immunoglobulin G4 anti-programmed cell death protein 1 monoclonal antibody. It is designed to minimise binding to Fcγ receptors on macrophages.

This design helps immune cells detect and fight tumours more effectively.

Tislelizumab has been approved by global health authorities including the China National Medical Products Administration, the European Medicines Agency and the US Food and Drug Administration for the treatment of advanced or metastatic esophageal squamous cell carcinoma.

It is under broad development for a range of cancer types.

A small molecule inhibitor of Bruton’s tyrosine kinase, Zanubrutinib has been approved to treat specific haematological malignancies.

Clinical studies have reinforced its favourable efficacy and safety profile.

BeiGene Asia-Pacific head and vice-president Adam Roach stated: “This collaboration is a testament to our shared vision of enhancing healthcare access across Asia.

“We take great pride in advancing mission-driven access, especially given the significant disease burden in India, where rising cancer rates require comprehensive healthcare solutions - a commitment we share with our partners at Glenmark.”